Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin
- PMID: 20030521
- DOI: 10.3109/08860220903216071
Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin
Abstract
Hepcidin is a small defensin-like peptide, the production of which by hepatocytes is modulated in response to anemia, hypoxia, or inflammation. Kidneys are involved in not only the synthesis of hepcidin, but they also may be involved in its elimination. A cross-sectional study was performed to assess prohepcidin and hepcidin in serum, urine, and ultrafiltrate/peritoneal effluent in relation to type of renal replacement therapy and prohepcidin and hepcidin correlations with renal function, iron status, and markers of inflammation.
Methods: Prohepcidin and hepcidin high-sensitivity CRP, TNF alpha, and IL-6 were measured using commercially available kits in 102 patients on hemodialyses, 17 on hemodiafiltration, 44 on peritoneal dialyses, and 22 healthy volunteers.
Results: In hemodialyzed and peritoneally dialyzed patients with residual renal function, serum prohepcidin (264.21 +/- 95.84 vs. 341.84 +/- 90.45 ng/mL, p < 0.01; 142.76 +/- 57.87 vs. 238.42 +/- 84.32 ng/mL, p < 0.01, respectively) and hepcidin (178.89 +/- 89.87 vs. 295.76 +/- 129.65 ng/mL, p < 0.01; 108.43 +/- 75.49 vs. 186.53 +/- 119.62 ng/mL, p < 0.01, respectively) were significantly lower than in anuric patients. In peritoneal effluent, prohepcidin level was significantly higher than in ultrafiltrate of HD/HDF patients. In multiple regression analysis, residual renal function, ferritin, and hsCRP were predictors of hepcidin in hemodialyzed patients, while residual renal function and ferritin were predictors of hepcidin in peritoneally dialyzed patients.
Conclusions: Residual renal function seems to play a pivotal role in hepcidin levels in dialyzed patients. In addition, the presence of low-grade inflammation, more pronounced in anuric patients, and functional iron deficiency may also contribute to the elevated hepcidin. The removal of prohepcidin with ultrafiltrate/peritoneal effluent may partially explain its lower concentration in peritoneal dialysis and hemodiafiltration.
Similar articles
-
Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis.Am J Hematol. 2006 Nov;81(11):832-7. doi: 10.1002/ajh.20657. Am J Hematol. 2006. PMID: 16929540
-
A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients.Transplant Proc. 2009 Oct;41(8):3056-9. doi: 10.1016/j.transproceed.2009.08.003. Transplant Proc. 2009. PMID: 19857675
-
Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.Am J Nephrol. 2008;28(1):115-21. doi: 10.1159/000109968. Epub 2007 Oct 17. Am J Nephrol. 2008. PMID: 17943020 Clinical Trial.
-
Hepcidin for clinicians.Clin J Am Soc Nephrol. 2009 Aug;4(8):1384-7. doi: 10.2215/CJN.02190309. Epub 2009 Jun 25. Clin J Am Soc Nephrol. 2009. PMID: 19556376 Review.
-
Increased hepcidin-25 and erythropoietin responsiveness in patients with cardio-renal anemia syndrome.Future Cardiol. 2010 Nov;6(6):769-71. doi: 10.2217/fca.10.97. Future Cardiol. 2010. PMID: 21142632 Review.
Cited by
-
Predictors and consequences of higher estimated glomerular filtration rate at dialysis initiation.Pediatr Nephrol. 2010 Jun;25(6):1153-61. doi: 10.1007/s00467-010-1459-4. Epub 2010 Feb 27. Pediatr Nephrol. 2010. PMID: 20191370
-
Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.PLoS One. 2012;7(7):e39783. doi: 10.1371/journal.pone.0039783. Epub 2012 Jul 13. PLoS One. 2012. PMID: 22808058 Free PMC article. Clinical Trial.
-
Iron status and anemia control are related to peritoneal membrane properties in peritoneally dialyzed patients.Front Med (Lausanne). 2023 Jul 6;10:1148094. doi: 10.3389/fmed.2023.1148094. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37484854 Free PMC article.
-
Biomarkers of iron metabolism in chronic kidney disease.Int Urol Nephrol. 2021 May;53(5):935-944. doi: 10.1007/s11255-020-02663-z. Epub 2020 Oct 6. Int Urol Nephrol. 2021. PMID: 33025407 Free PMC article. Review.
-
Iron and Chronic Kidney Disease: Still a Challenge.Front Med (Lausanne). 2020 Dec 18;7:565135. doi: 10.3389/fmed.2020.565135. eCollection 2020. Front Med (Lausanne). 2020. PMID: 33392212 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous